SectorBiological Technology
Established Date--
Listing Date09/01/2026
ExchangeNASDAQ Stock Exchange
Full-time Employees79
Fiscal Year Ends31/12
Security TypeCommon stock
Office address17 Drydock Avenue
Suite 17-401 Boston
Massachusetts 02210
Business
IntroductionAktis Oncology, Inc. was incorporated under the laws of the State of Delaware in August 2020. The company is a clinical-stage oncology company that leverages its proprietary small protein platform to develop targeted radiopharmaceuticals. Its lead drug candidate [225Ac] Ac-AKY-1189 targets Nectin-4 and is currently in Phase 1 b clinical development for urothelial carcinoma and other solid tumors expressing Nectin-4.
